Veradigm discloses ICFR weakness related to rev rec software tool

AuditInspectionFeature

Healthcare technology company Veradigm disclosed it expects it misstated revenue by approximately $40 million during its 2021 and 2022 reporting periods.

Veradigm previously disclosed it misstated revenues going back to the third quarter of 2021 by $20 million, but an expanded audit discovered additional problems leading to the updated total, the company stated in a regulatory filing with the Securities and Exchange Commission (SEC) on Wednesday.

The company said its quarterly reports and year-end reports from March 2021 through September 2022 should not be relied on. The misstatements were made because of internal control over financial reporting (ICFR) deficiencies, the company said.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.